View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Bibliography 265<br />
Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced<br />
HBeAg clearance. J Med Virol. 2007 Aug;79(8):1055-63.<br />
86. Bergmann JF, Vrolijk JM, van der Schaar P, Vroom B, van Hoek B, van der Sluys Veer A,<br />
de Vries RA, Verhey E, Hansen BE, Brouwer JT, Janssen HL, Schalm SW, de Knegt RJ.<br />
Gamma-glutamyltransferase and rapid virological response as predictors of successful<br />
treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C<br />
non-responders. Liver Int. 2007 Nov;27(9):1217-25. PMID: 17919233<br />
87. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T,<br />
Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. Sustained<br />
HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with<br />
peginterferon alpha-2b.Gastroenterology. 2008 Aug;135(2):459-67. Epub 2008 May 15.<br />
PMID: 18585385<br />
88. Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, de Knegt RJ,<br />
Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL. Increased risk of hepatocellular<br />
carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology.<br />
2008 Jun;47(6):1856-62. PMID: 18506898<br />
89. ter Borg MJ, Hansen BE, Bigot G, Haagmans BL, Janssen HL. ALT and viral load decline<br />
during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B. J Clin Virol.<br />
2008 Jun;42(2):160-4. Epub 2008 Mar 24. PMID: 18359663<br />
90. Murad SD, Luong TK, Pattynama PM, Hansen BE, van Buuren HR, Janssen HL. Long-term<br />
outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in<br />
Budd-Chiari syndrome. Liver Int. 2008 Feb;28(2):249-56. PMID: 18251982<br />
91. ter Borg MJ, Hansen BE, Herrmann E, Zeuzem S, Cakaloglu Y, Karayalcin S, Flisiak R, van’<br />
t Veen A, de Man RA, Schalm SW, Janssen HL, Haagmans BL; HBV 99-01 Study Group.<br />
Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in<br />
patients with HBeag-positive chronic hepatitis B. Antivir Ther. 2007;12(8):1285-94. PMID:<br />
18240868<br />
92. Spaander MC, Murad SD, van Buuren HR, Hansen BE, Kuipers EJ, Janssen HL. Endoscopic<br />
treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic<br />
portal vein thrombosis: a long-term follow-up study. Gastrointest Endosc. 2008<br />
May;67(6):821-7. Epub 2008 Jan 18. PMID: 18206153<br />
93. de Vries-Sluijs TE, Hansen BE, van Doornum GJ, Springeling T, Evertsz NM, de Man RA, van<br />
der Ende ME. A prospective open study of the effi cacy of high-dose recombinant hepatitis<br />
B rechallenge vaccination in HIV-infected patients. Infect Dis. 2008 Jan 15;197(2):292-4.<br />
PMID: 18177248<br />
94. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen<br />
BE, Schalm SW, Janssen HL. Sustained virologic response and clinical outcomes in patients<br />
with chronic hepatitis C and advanced fi brosis.Ann Intern Med. 2007 Nov 20;147(10):677-84.<br />
Summary for patients in: Ann Intern Med. 2007 Nov 20;147(10):I47.PMID: 18025443<br />
95. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. Factors<br />
that Predict Response of Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B